



Evonetix appoints Dr Michael Daniels as Head of Product Management

CAMBRIDGE, UK 30 March 2021 – EVONETIX LTD ('Evonetix'), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the appointment of Michael Daniels, PhD, as Head of Product Management. In this role, Dr Daniels will be focused on the development and introduction of Evonetix's first product, a DNA desktop writer. He will work closely with the prospective customers and users of the Company's products as well as the team's engineers and research scientists.

Dr Daniels brings with him over 15 years' experience of marketing and product management across the biotechnology sector. His previous roles include Director of Marketing and Product Management at Arcis Biotechnology, Senior Manager of Marketing and Business Development at Cancer Research UK, and Director of Marketing and Product Management at Thermo Fisher Scientific, as well as leading various projects at GE Healthcare Life Sciences. Dr Daniels holds a PhD from the Department of Biochemistry and Genetics at the University of Newcastle. He has also completed numerous professional qualifications and training in marketing, management, and IP law.

Dr Daniels will be responsible for defining the roadmap for Evonetix's DNA desktop writer and developing the definition and vision of the Company's first products. He will also manage the Company's early access programme, building relationships with a small number of users and collaborators to further develop and refine the company's product portfolio.

Dr Tim Brears, CEO at Evonetix, commented: *"It is a pleasure to welcome Mike to the team. I am confident that his vast experience and expertise will make him a key asset for Evonetix, as we continue to develop our first product. I look forward to working with Mike on the progression of our DNA desktop writer to commercialisation."*

Dr Michael Daniels, Head of Product Management at Evonetix, said: *"Evonetix's DNA desktop writer has the potential to revolutionise synthetic biology, and I look forward to working with the team to guide its development and commercialisation. It is an exciting time to be joining the Company."*

For more information about Evonetix, please visit: www.evonetix.com.

ENDS



*Dr Michael Daniels,
Head of Product Management at Evonetix*

For a high-resolution image please contact Zyme Communications

For further information, please contact:

For Evonetix

Lorna Cuddon

Zyme Communications

Tel: +44(0)7811996942

Email: lorna.cuddon@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

Notes to Editors

About Evonetix Ltd - www.evonetix.com

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale. The company's platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology.

The proprietary Evonetix approach utilises a silicon chip, made by MEMS processing, that integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or 'pixels' on the chip surface in a highly parallel fashion. The approach is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, providing accuracy that is several orders of magnitude better than the conventional approach.

The Evonetix DNA writer will be a desktop device, available to every researcher, and providing scalable, accurate DNA synthesis to enable biological systems to be engineered with unprecedented accuracy and scale – this is third-generation DNA synthesis.

About synthetic biology

With the huge increase in DNA sequence information available to mankind over the past ten years, there now exists an unprecedented opportunity to, for example, engineer metabolic pathways and organisms, improve industrial processes, create new processes and engineer genomes with new or improved traits. This opportunity, known as synthetic biology, is estimated to grow rapidly over the coming years, reaching \$40 billion in value in the mid-2020s. Synthetic biology will have a massive impact across many industries and will be fundamental to helping us manage the Earth's resources.

However, only a highly disruptive technology is likely to achieve the significant improvements in DNA synthesis required to enable and facilitate these opportunities. Evonetix believes that, by providing high-fidelity DNA at scale, without the need for post-synthesis error correction, it will be well placed to capture a significant part of the growing multibillion-dollar synthetic biology opportunity.